Barriers to interferon-α therapy are higher in intravenous drug users than in other patients with acute hepatitis C
- 31 March 2005
- journal article
- clinical trial
- Published by Elsevier in Journal of Hepatology
- Vol. 42 (3) , 323-328
- https://doi.org/10.1016/j.jhep.2004.11.018
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Treatment of acute hepatitis C with interferon α‐2b: early initiation of treatment is the most effective predictive factor of sustained viral responseAlimentary Pharmacology & Therapeutics, 2004
- Short-term interferon-alfa therapy for acute hepatitis C: A randomized controlled trialHepatology, 2004
- Treatment of hepatitis C. The 2002 French consensusGut, 2003
- Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance1 1The Bundesministerium für Bildung und Forschung and the European Union, as sponsors of the study, had no role in study design, data collection, analysis, or interpretation or in the writing and the decision to submit the report for publication.Gastroenterology, 2003
- Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral loadHepatology, 2003
- Therapy of acute hepatitis CHepatology, 2002
- National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10-12, 2002Hepatology, 2002
- Treatment of Acute Hepatitis C with Interferon Alfa-2bNew England Journal of Medicine, 2001
- Hepatitis C Virus–Associated Fulminant Hepatic FailureNew England Journal of Medicine, 1996
- Effects of interferon beta on non-A, non-B acute hepatitis: A prospective, randomized, controlled-dose studyGastroenterology, 1994